Which has higher earnings & valuation, IMMP or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $16.40M 2.33 -$53.82M N/A N/A CytoMed Therapeutics $250K 40.88 -$3.10M N/A N/A

Is IMMP or GDTC more profitable?

Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A CytoMed Therapeutics N/A N/A N/A

Which has preferable earnings and valuation, MGX or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than Metagenomi. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Metagenomi $13.56M 3.15 -$87.87M -$2.49 N/A CytoMed Therapeutics $250K 40.88 -$3.10M N/A N/A

Which has stronger earnings and valuation, MCRB or GDTC?

Seres Therapeutics has higher revenue and earnings than CytoMed Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Seres Therapeutics $790K 46.31 $5.70M -$2.43 N/A CytoMed Therapeutics $250K 40.88 -$3.10M N/A N/A

Which has better earnings & valuation, EDSA or GDTC?

CytoMed Therapeutics has higher revenue and earnings than Edesa Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edesa Biotech N/A N/A -$7.19M -$1.69 N/A CytoMed Therapeutics $250K 40.88 -$3.10M N/A N/A

Is EDSA or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -560.22% -105.74% CytoMed Therapeutics N/A N/A N/A

Do analysts prefer IZTC or GDTC?

CytoMed Therapeutics has a consensus target price of $4.16, indicating a potential upside of 381.48%. Given CytoMed Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytoMed Therapeutics is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, IZTC or GDTC?

Invizyne Technologies has higher earnings, but lower revenue than CytoMed Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A CytoMed Therapeutics $250K 40.88 -$3.10M N/A N/A

Is IZTC or GDTC more profitable?

Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A CytoMed Therapeutics N/A N/A N/A

CytoMed Therapeutics (GDTC) Competitors

$0.86 -0.05 (-5.05%)

As of 10:35 AM Eastern

Compare

GDTC vs. IMMP, MGX, MCRB, EDSA, and IZTC

Should you buy CytoMed Therapeutics stock or one of its competitors? CytoMed Therapeutics's main competitors and comparable companies include Prima BioMed (IMMP), Metagenomi (MGX), Seres Therapeutics (MCRB), Edesa Biotech (EDSA), and Invizyne Technologies (IZTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CytoMed Therapeutics compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

CytoMed Therapeutics has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$16.40M	2.33	-$53.82M	N/A	N/A
CytoMed Therapeutics	$250K	40.88	-$3.10M	N/A	N/A

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
CytoMed Therapeutics	N/A	N/A	N/A

Prima BioMed currently has a consensus price target of $5.50, suggesting a potential upside of 2,023.55%. CytoMed Therapeutics has a consensus price target of $4.16, suggesting a potential upside of 381.48%. Given Prima BioMed's stronger consensus rating and higher possible upside, research analysts plainly believe Prima BioMed is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Prima BioMed has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market.

In the previous week, Prima BioMed had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 1 mentions for Prima BioMed and 0 mentions for CytoMed Therapeutics. Prima BioMed's average media sentiment score of 1.00 beat CytoMed Therapeutics' score of 0.00 indicating that Prima BioMed is being referred to more favorably in the media.

Company	Overall Sentiment
Prima BioMed	Positive
CytoMed Therapeutics	Neutral

Summary

Prima BioMed beats CytoMed Therapeutics on 9 of the 11 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Metagenomi currently has a consensus price target of $6.00, suggesting a potential upside of 430.97%. CytoMed Therapeutics has a consensus price target of $4.16, suggesting a potential upside of 381.48%. Given Metagenomi's stronger consensus rating and higher possible upside, equities analysts plainly believe Metagenomi is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CytoMed Therapeutics has lower revenue, but higher earnings than Metagenomi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$13.56M	3.15	-$87.87M	-$2.49	N/A
CytoMed Therapeutics	$250K	40.88	-$3.10M	N/A	N/A

In the previous week, Metagenomi had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 1 mentions for Metagenomi and 0 mentions for CytoMed Therapeutics. Metagenomi's average media sentiment score of 0.00 equaled CytoMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
Metagenomi	Neutral
CytoMed Therapeutics	Neutral

0.0% of CytoMed Therapeutics shares are held by institutional investors. 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Metagenomi has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market.

CytoMed Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. CytoMed Therapeutics' return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
CytoMed Therapeutics	N/A	N/A	N/A

Summary

Metagenomi beats CytoMed Therapeutics on 8 of the 14 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Seres Therapeutics has higher revenue and earnings than CytoMed Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	46.31	$5.70M	-$2.43	N/A
CytoMed Therapeutics	$250K	40.88	-$3.10M	N/A	N/A

Seres Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market.

CytoMed Therapeutics has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. CytoMed Therapeutics' return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
CytoMed Therapeutics	N/A	N/A	N/A

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Seres Therapeutics had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 1 mentions for Seres Therapeutics and 0 mentions for CytoMed Therapeutics. Seres Therapeutics' average media sentiment score of 0.94 beat CytoMed Therapeutics' score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Seres Therapeutics	Positive
CytoMed Therapeutics	Neutral

Seres Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 367.03%. CytoMed Therapeutics has a consensus price target of $4.16, suggesting a potential upside of 381.48%. Given CytoMed Therapeutics' higher probable upside, analysts clearly believe CytoMed Therapeutics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Seres Therapeutics beats CytoMed Therapeutics on 10 of the 14 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

In the previous week, Edesa Biotech had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 1 mentions for Edesa Biotech and 0 mentions for CytoMed Therapeutics. Edesa Biotech's average media sentiment score of 0.63 beat CytoMed Therapeutics' score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Edesa Biotech	Positive
CytoMed Therapeutics	Neutral

CytoMed Therapeutics has higher revenue and earnings than Edesa Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
CytoMed Therapeutics	$250K	40.88	-$3.10M	N/A	N/A

Edesa Biotech has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market.

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CytoMed Therapeutics' return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
CytoMed Therapeutics	N/A	N/A	N/A

Edesa Biotech presently has a consensus target price of $5.00, indicating a potential upside of 25.79%. CytoMed Therapeutics has a consensus target price of $4.16, indicating a potential upside of 381.48%. Given CytoMed Therapeutics' higher possible upside, analysts clearly believe CytoMed Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Edesa Biotech beats CytoMed Therapeutics on 7 of the 12 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

0.0% of CytoMed Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Invizyne Technologies has higher earnings, but lower revenue than CytoMed Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
CytoMed Therapeutics	$250K	40.88	-$3.10M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
CytoMed Therapeutics	N/A	N/A	N/A

CytoMed Therapeutics has a consensus target price of $4.16, indicating a potential upside of 381.48%. Given CytoMed Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytoMed Therapeutics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Invizyne Technologies' average media sentiment score of 0.00 equaled CytoMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
Invizyne Technologies	Neutral
CytoMed Therapeutics	Neutral

Summary

CytoMed Therapeutics beats Invizyne Technologies on 5 of the 5 factors compared between the two stocks.

Get CytoMed Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GDTC vs. The Competition

Export

Metric	CytoMed Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.22M	$3.91B	$7.27B	$13.03B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	N/A	14.13	274.95	25.63
Price / Sales	40.88	1,446.16	669.16	97.27
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.92	15.01	10.32	6.26
Net Income	-$3.10M	-$22.82M	$3.49B	$360.12M
7 Day Performance	-2.48%	-2.72%	-1.33%	-0.42%
1 Month Performance	-13.60%	-7.12%	-3.71%	-3.75%
1 Year Performance	-57.44%	29.24%	14.41%	4.84%

CytoMed Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GDTC CytoMed Therapeutics	1.68 of 5 stars	$0.86 -5.1%	$4.16 +381.5%	-55.6%	$10.22M	$250K	N/A	42
IMMP Prima BioMed	2.3954 of 5 stars	$0.29 -9.8%	$5.50 +1,823.1%	-83.9%	$42.15M	$16.40M	N/A	2,021	Positive News
MGX Metagenomi	3.2774 of 5 stars	$1.11 -2.2%	$6.00 +443.0%	-48.2%	$41.74M	$13.56M	N/A	113	Positive News
MCRB Seres Therapeutics	3.0541 of 5 stars	$4.01 -2.3%	$17.00 +324.5%	-78.4%	$40.25M	$790K	N/A	66	Gap Down
EDSA Edesa Biotech	2.3335 of 5 stars	$4.11 -0.7%	$5.00 +21.7%	+66.8%	$39.63M	N/A	N/A	17	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GDTC) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytoMed Therapeutics (GDTC) Competitors

GDTC vs. IMMP, MGX, MCRB, EDSA, and IZTC

How does CytoMed Therapeutics compare to Prima BioMed?

Summary

How does CytoMed Therapeutics compare to Metagenomi?

Summary

How does CytoMed Therapeutics compare to Seres Therapeutics?

Summary

How does CytoMed Therapeutics compare to Edesa Biotech?

Summary

How does CytoMed Therapeutics compare to Invizyne Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC vs. The Competition

CytoMed Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytoMed Therapeutics (GDTC) Competitors

GDTC vs. IMMP, MGX, MCRB, EDSA, and IZTC

How does CytoMed Therapeutics compare to Prima BioMed?

Which has higher earnings & valuation, IMMP or GDTC?

Do institutionals & insiders have more ownership in IMMP or GDTC?

Is IMMP or GDTC more profitable?

Do analysts prefer IMMP or GDTC?

Which has more risk and volatility, IMMP or GDTC?

Does the media refer more to IMMP or GDTC?

Summary

How does CytoMed Therapeutics compare to Metagenomi?

Do analysts rate MGX or GDTC?

Which has preferable earnings and valuation, MGX or GDTC?

Does the media prefer MGX or GDTC?

Do institutionals and insiders have more ownership in MGX or GDTC?

Which has more volatility and risk, MGX or GDTC?

Is MGX or GDTC more profitable?

Summary

How does CytoMed Therapeutics compare to Seres Therapeutics?

Which has stronger earnings and valuation, MCRB or GDTC?

Which has more risk & volatility, MCRB or GDTC?

Is MCRB or GDTC more profitable?

Do insiders & institutionals have more ownership in MCRB or GDTC?

Does the media prefer MCRB or GDTC?

Do analysts prefer MCRB or GDTC?

Summary

How does CytoMed Therapeutics compare to Edesa Biotech?

Does the media prefer EDSA or GDTC?

Which has better earnings & valuation, EDSA or GDTC?

Which has more risk & volatility, EDSA or GDTC?

Do insiders and institutionals believe in EDSA or GDTC?

Is EDSA or GDTC more profitable?

Do analysts rate EDSA or GDTC?

Summary

How does CytoMed Therapeutics compare to Invizyne Technologies?

Do institutionals and insiders believe in IZTC or GDTC?

Which has higher earnings & valuation, IZTC or GDTC?

Is IZTC or GDTC more profitable?

Do analysts prefer IZTC or GDTC?

Does the media prefer IZTC or GDTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC vs. The Competition

CytoMed Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools